Cargando…

Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice

BACKGROUND: Chagas disease is a major health problem in Latin America, and an emerging infectious disease in the US. Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and identified antigens that exhibited the characteristics of vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shivali, Garg, Nisha Jain
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919396/
https://www.ncbi.nlm.nih.gov/pubmed/20706586
http://dx.doi.org/10.1371/journal.pntd.0000797
_version_ 1782185175321411584
author Gupta, Shivali
Garg, Nisha Jain
author_facet Gupta, Shivali
Garg, Nisha Jain
author_sort Gupta, Shivali
collection PubMed
description BACKGROUND: Chagas disease is a major health problem in Latin America, and an emerging infectious disease in the US. Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and identified antigens that exhibited the characteristics of vaccine candidates. METHODOLOGY: We investigated the protective efficacy of a multi-component DNA-prime/protein-boost vaccine (TcVac2) constituted of the selected candidates and cytokine (IL-12 and GM-CSF) expression plasmids in a murine model. C57BL/6 mice were immunized with antigen-encoding plasmids plus cytokine adjuvants, followed by recombinant proteins; and two-weeks later, challenged with T. cruzi trypomastigotes. ELISA and flow cytometry were employed to measure humoral (antibody isotypes) and cellular (lymphocyte proliferation, CD4(+) and CD8(+) T cell phenotype and cytokines) responses. Myocardial pathology was evaluated by H&E and Masson's trichrome staining. PRINCIPAL FINDINGS: TcVac2 induced a strong antigen-specific antibody response (IgG2b>IgG1) and a moderate level of lymphocyte proliferation in mice. Upon challenge infection, TcVac2-vaccinated mice expanded the IgG2b/IgG1 antibodies and elicited a substantial CD8(+) T cell response associated with type 1 cytokines (IFN-γ and TNF-α) that resulted in control of acute parasite burden. During chronic phase, antibody response persisted, splenic activation of CD8(+) T cells and IFN-γ/TNF-α cytokines subsided, and IL-4/IL-10 cytokines became dominant in vaccinated mice. The tissue parasitism, inflammation, and fibrosis in heart and skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological techniques. In comparison, mice injected with vector or cytokines only responded to T. cruzi by elicitation of a mixed (type 1/type 2) antibody, T cell and cytokine response, and exhibited persistent parasite burden and immunopathology in the myocardium. CONCLUSION: TcVac2-induced activation of type 1 antibody and lymphocyte responses provided resistance to acute T. cruzi infection, and consequently, prevented the evolution of chronic immunopathology associated with parasite persistence in chagasic hearts.
format Text
id pubmed-2919396
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29193962010-08-12 Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice Gupta, Shivali Garg, Nisha Jain PLoS Negl Trop Dis Research Article BACKGROUND: Chagas disease is a major health problem in Latin America, and an emerging infectious disease in the US. Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and identified antigens that exhibited the characteristics of vaccine candidates. METHODOLOGY: We investigated the protective efficacy of a multi-component DNA-prime/protein-boost vaccine (TcVac2) constituted of the selected candidates and cytokine (IL-12 and GM-CSF) expression plasmids in a murine model. C57BL/6 mice were immunized with antigen-encoding plasmids plus cytokine adjuvants, followed by recombinant proteins; and two-weeks later, challenged with T. cruzi trypomastigotes. ELISA and flow cytometry were employed to measure humoral (antibody isotypes) and cellular (lymphocyte proliferation, CD4(+) and CD8(+) T cell phenotype and cytokines) responses. Myocardial pathology was evaluated by H&E and Masson's trichrome staining. PRINCIPAL FINDINGS: TcVac2 induced a strong antigen-specific antibody response (IgG2b>IgG1) and a moderate level of lymphocyte proliferation in mice. Upon challenge infection, TcVac2-vaccinated mice expanded the IgG2b/IgG1 antibodies and elicited a substantial CD8(+) T cell response associated with type 1 cytokines (IFN-γ and TNF-α) that resulted in control of acute parasite burden. During chronic phase, antibody response persisted, splenic activation of CD8(+) T cells and IFN-γ/TNF-α cytokines subsided, and IL-4/IL-10 cytokines became dominant in vaccinated mice. The tissue parasitism, inflammation, and fibrosis in heart and skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological techniques. In comparison, mice injected with vector or cytokines only responded to T. cruzi by elicitation of a mixed (type 1/type 2) antibody, T cell and cytokine response, and exhibited persistent parasite burden and immunopathology in the myocardium. CONCLUSION: TcVac2-induced activation of type 1 antibody and lymphocyte responses provided resistance to acute T. cruzi infection, and consequently, prevented the evolution of chronic immunopathology associated with parasite persistence in chagasic hearts. Public Library of Science 2010-08-10 /pmc/articles/PMC2919396/ /pubmed/20706586 http://dx.doi.org/10.1371/journal.pntd.0000797 Text en Gupta, Garg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gupta, Shivali
Garg, Nisha Jain
Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title_full Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title_fullStr Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title_full_unstemmed Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title_short Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice
title_sort prophylactic efficacy of tcvac2 against trypanosoma cruzi in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919396/
https://www.ncbi.nlm.nih.gov/pubmed/20706586
http://dx.doi.org/10.1371/journal.pntd.0000797
work_keys_str_mv AT guptashivali prophylacticefficacyoftcvac2againsttrypanosomacruziinmice
AT gargnishajain prophylacticefficacyoftcvac2againsttrypanosomacruziinmice